JP Patent

JP7374885B2 — 子宮内膜症、子宮筋腫、多嚢胞性卵巣症候群又は腺筋症を治療するための医薬製剤

Assigned to AbbVie Inc · Expires 2023-11-07 · 3y expired

What this patent protects

Patent listed against elagolix-sodium.

Drugs covered by this patent

elagolix-sodium (ELAGOLIX SODIUM)

Patent Metadata

Patent number: JP7374885B2
Jurisdiction: JP
Classification: —
Expires: 2023-11-07
Drug substance claim: No
Drug product claim: No
Assignee: AbbVie Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.